CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 11, 2020--
Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the closing of its initial public offering of 12,176,471 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,588,235 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to Beam Therapeutics from the offering were approximately $207 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Beam Therapeutics. Beam Therapeutics’ common stock is listed on The Nasdaq Global Select Market under the ticker symbol “BEAM.”
J.P. Morgan, Jefferies and Barclays acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering.
A registration statement relating to the shares sold in this offering became effective by the Securities and Exchange Commission on February 5, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (866) 803-9204, or by emailing firstname.lastname@example.org; Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at 877-821-7388 or by email at email@example.com; or Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-888-603-5847, or email: Barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification of these securities under the securities laws of any such state or other jurisdiction.
About Beam Therapeutics
Beam Therapeutics (Nasdaq:BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization focused on its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005561/en/
Source: Beam Therapeutics Inc.
THRUST Strategic Communications